



Therapeutic Targeting of RNA Polymerase I Transcription, Ribosome Biogenesis and Function

Guest Editors:

Dr. Denis Drygin

Pimera Therapeutics, 7875
Highland Village Place, Suite 412,
San Diego, CA 92129, USA

Prof. Dr. Ross Hannan

The Division of Genome Science
and Cancer, The John Curtin
School of Medical Research, The
Australian National University,
Acton, Canberra 2601, Australia

Deadline for manuscript
submissions:

15 May 2024

Message from the Guest Editors

Dear Colleagues,

Since the original late 19th century publication linking nucleolar hypertrophy to carcinogenesis, multiple groups have extensively worked on expanding the knowledge in this field. With two selective inhibitors of RNA polymerase I (Pol I) transcription, CX-5461 and PMR-116 being in clinical development, the promise of the therapeutic targeting of ribosome biogenesis, of which Pol I transcription is a rate-limiting step, is close to be realized.

We welcome original research and review papers, as well as reviews on subjects linking the deregulation of RNA polymerase I (Pol I) transcription and ribosome biogenesis to various pathologies, as well as the potential of compounds that target these processes as therapeutic agents.

We are looking forward to receiving your contributions!

Dr. Denis Drygin
Prof. Dr. Ross Hannan
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)